Effective dosing of l-carnitine in the secondary prevention of cardiovascular disease: A systematic review and meta-analysis

BMC Cardiovascular Disorders

Volumn 14, Issue 1, 2014, Pages

  Shang, Ruiping ^a   Sun, Zhiqi ^a   Li, Hui ^a  

^a Daqing Oilfield General Hospital   (China)

Author keywords

Cardiovascular; Carnitine; Dosage; Dose; Dosing; L carnitine; MI; Myocardial infarction

Indexed keywords

CARNITINE; PLACEBO; CARDIOVASCULAR AGENT;

ACUTE HEART INFARCTION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG DOSE COMPARISON; HEART FAILURE; HEART REINFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; META ANALYSIS; MORBIDITY; MORTALITY; SECONDARY PREVENTION; SYSTEMATIC REVIEW; UNSTABLE ANGINA PECTORIS; CARDIOVASCULAR DISEASES; CHI SQUARE DISTRIBUTION; DOSE CALCULATION; DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PROCEDURES; RECURRENT DISEASE; RISK; RISK FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CARNITINE; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; HUMANS; ODDS RATIO; RECURRENCE; RISK FACTORS; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84904445760     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-14-88     Document Type: Article

References (32)

1. Gersh BJ, Sliwa K, Mayosi BM, Yusuf S: Novel therapeutic concepts. The epidemic of cardiovascular disease in the developing world: global implications. Eur Heart J 2010, 31(6):642-648.
2. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Woo YJ: Forecasting the future of cardiovascular disease in the United States a policy statement from the American heart association. Circulation 2011, 123(8):933-944.
3. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Teo KK: Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011, 378(9798):1231-1243.
4. Flanagan JL, Simmons PA, Vehige J, Willcox MD, Garrett Q: Review Role of carnitine in disease. 2010.
5. Colonna P, Iliceto S: Myocardial infarction and left ventricular remodeling: results of the CEDIM trial. Carnitine Ecocardiografia Digitalizzata Infarto Miocardico. Am Heart J 2000, 139:S124-S130.
6. Xue YZ, Wang LX, Liu HZ, Qi XW, Wang XH, Ren HZ: L-carnitine as an adjunct therapy to percutaneous coronary intervention for non-ST elevation myocardial infarction. Cardiovasc Drugs Ther 2007, 21:445-448.
7. DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH: L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clinic Proc 2013, 88(6):5444-51.
8. Rebouche CJ: Kinetics, pharmacokinetics, and regulation of l-carnitine and acetyl-l-carnitine metabolism. Ann N Y Acad Sci 2004, 1033(1):30-41.
9. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700.
10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17(1):1-12
11. Higgins JP, Green S: Cochran Handbook for Systematic Review of Interventions: Assessing Risk of Bias in Included Studies. 500th edition. Hoboken, NJ: John Wiley & Sons Inc; 2008.
12. Davini P, Bigalli A, Lamanna F, Boem A: Controlled study on L-carnitine therapeutic efficacy in post-infarction. Drugs Exp Clin Res 1992, 18(8):355-365. PubMed PMID: 1292918. Epub 1992/01/01. eng.
13. Iliceto S, Scrutinio D, Bruzzi P, D'Ambrosio G, Boni L, Di Biase M, Biasco G, Hugenholtz PG, Rizzon P: Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol 1995, 26(2):380-387. PubMed PMID: 7608438. Epub 1995/08/01. eng.
14. Singh RB, Niaz MA, Agarwal P, Beegum R, Rastogi SS, Sachan DS: A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction. Postgrad Med J 1996, 72(843):45-50. PubMed PMID: 8746285. Pubmed Central PMCID: 2398308. Epub 1996/01/01. eng.
15. Iyer R, Gupta A, Khan A, Hiremath S, Lokhandwala Y: Does left ventricular function improve with L-carnitine after acute myocardial infarction? J Postgrad Med 1999, 45(2):38-41. PubMed PMID: 10734331. Epub 2000/03/29. eng.
16. Tarantini G, Scrutinio D, Bruzzi P, Boni L, Rizzon P, Iliceto S: Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial. Cardiology 2006, 106(4):215-223. PubMed PMID: 16685128. Epub 2006/05/11. eng.
17. Evans AM, Fornasini G: Pharmacokinetics of L-carnitine. Clin Pharmacokinet 2003, 42(11):941-967.
18. Koeth RA, Wang Z, Levison BS, Buffa JA, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ, Hazen SL: Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013, 19(5):576-585.
19. Rebouche CJ, Chenard CA: Metabolic fate of dietary carnitine in human adults: identification and quantification of urinary and fecal metabolites. J Nutr 1991, 121(4):539-546.
20. Bennett BJ, Vallim TQ, Wang Z, Shih DM, Meng Y, Gregory J, Allayee H, Lee R, Graham M, Crooke R, Edwards PA, Hazen SL, Lusis AJ: Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab 2013, 17(1):49-60.
21. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL: Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013, 368(17):1575-1584.
22. Zhu Y, Jameson E, Crosatti M, Schäfer H, Rajakumar K, Bugg TD, Chen Y: Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota. Proc Natl Acad Sci 2014, 111(11):4268-4273.
23. Brass EP: Supplemental carnitine and exercise. Am J Clin Nutr 2000, 72(2):618s-623s.
24. Friolet R, Hoppeler H, Krähenbühl S: Relationship between the coenzyme A and the carnitine pools in human skeletal muscle at rest and after exhaustive exercise under normoxic and acutely hypoxic conditions. J Clin Investig 1994, 94(4):1490.
25. Arenas J, Huertas R, Campos Y, Díaz AE, Villalón JM, Vilas E: Effects of L-carnitine on the pyruvate dehydrogenase complex and carnitine palmitoyl transferase activities in muscle of endurance athletes. FEBS Lett 1994, 341(1):91-93.
26. Huertas R, Campos Y, Díaz E, Esteban J, Vechietti L, Montanari G, D'Iddio S, Corsi M, Arenas J: Respiratory chain enzymes in muscle of endurance athletes: effect of L-carnitine. Biochem Biophys Res Commun 1992, 188(1):102-107.
27. Stephens FB, Wall BT, Marimuthu K, Shannon CE, Constantin-Teodosiu D, Macdonald IA, Greenhaff PL: Skeletal muscle carnitine loading increases energy expenditure, modulates fuel metabolism gene networks and prevents body fat accumulation in humans. J Physiol 2013, 591(18):4655-4666.
28. Wall BT, Stephens FB, Constantin-Teodosiu D, Marimuthu K, Macdonald IA, Greenhaff PL: Chronic oral ingestion of l-carnitine and carbohydrate increases muscle carnitine content and alters muscle fuel metabolism during exercise in humans. J Physiol 2011, 589(4):963-973.
29. Stephens FB, Constantin-Teodosiu D, Laithwaite D, Simpson EJ, Greenhaff PL: Insulin stimulates L-carnitine accumulation in human skeletal muscle. FASEB J 2006, 20(2):377-379.
30. Ueland T, Svardal A, Øie E, Askevold ET, Nymoen SH, Bjørndal B, Dahl CP, Gullestad L, Berge RK, Aukrust P: Disturbed carnitine regulation in chronic heart failure-increased plasma levels of palmitoyl-carnitine are associated with poor prognosis. Int J Cardiol 2013, 167(5):1892-1899.
31. Pons R, Darryl C: Primary and secondary carnitine deficiency syndromes. J Child Neurol 1995, 10(2 suppl):2S8-2S24.
32. Evans A: Dialysis-related carnitine disorder and levocarnitine pharmacology. Am J Kidney Dis 2003, 41:S13-S26.